Otros artículos de Pilar Navarro Medrano
Martínez-Bosch N and Navarro P. Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard. Oncoimmunology 3(8): e952201, 2014.
Martínez-Bosch N, Iglesias M, Munné-Collado J, Martínez-Cáceres C, Moreno M, Guerra C, Yélamos J and Navarro P. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. J Pathology, 234(2): 214-27, 2014.
Martínez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz-Zapater E, André S, Gabius H-J, Hwang RF, Poirier F, Munné-Collado J, Iglesias M, Navas C, Guerra C, Fernández-Zapico ME and Navarro P. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Research, 74(13):3512-24, 2014.
Montolio M, Gregori-Puigjané E, Pineda D, Mestres J and Navarro P. Identification of small molecule inhibitors of amyloid b-induced neuronal apoptosis acting through the imidazoline I(2) receptor. J Med Chem 55 (22): 9838-46, 2012.
Pineda D, Ampurdanés C, Manel G. Medina G M, Serratosa J, Tusell J, Saura J, Planas A and Navarro P. Tissue plasminogen activator (tPA) induces microglial inflammation via a non-catalytic molecular mechanism involving activation of MAPKs and AKT signalling pathways and AnnexinA2 and Galectin-1 receptors. Glia 60(4):526-40, 2012.
Ortiz-Zapater E, Pineda D, Martínez-Bosch N, Iglesias M, Alameda F, Moreno M, Eliscovich C, Eyras E, Real FX, Méndez R and Navarro P. Key contribution of CPEB4-mediated translational control to cancer progression, Nat. Med., 18(1):83-90, 2011.
Roda O, Ortiz-Zapater E, Martínez-Bosch N, Gutiérrez-Gallego R, Vila-Perelló M, Ampurdanés C, Gabius HJ, André S, Andreu D, Real FX and Navarro P. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology, 136(4):1379-1390, 2009.
Ortiz-Zapater E, Peiro S, Roda O, Corominas JM, Aguilar S, Ampurdanes C, Real FX and Navarro P. Tissue plasminogen activator induces pancreas cancer cell proliferation by a non-catalytic mechanism that requires ERK1/2 activation through Epidermal Growth Factor Receptor and Annexin A2, Am. J. Pathol. 170:1573-84, 2007.
Medina MG, Ledesma, MD, Dominguez JE, Medina M, Zagra D, Alameda F, Dotti CG and Navarro P. Tissue plasminogen activator mediates amyloid induced neurotoxicity via sustained Erk1/2 activation. The EMBO J., 24:1706-1716, 2005.
Aguilar S, Corominas JM, Malats N, Dufresne M, Real FX and Navarro P. The tissue plasminogen activator system in murine exocrine pancreas cancer:selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 165(4): 1129-1139, 2004.
Para comunicarse con Pilar Navarro Medrano mencionar a SIIC como
referencia:
pnavarro@imim.es
Autor invitado
19 de abril, 2012
Descripción aprobada
28 de octubre, 2015
Reedición siicsalud
9 de septiembre, 2022